Endo Pharmaceuticals Holdings Inc.

Published Date: 14/06/2011
Category: Drug Delivery & Devices

Research Report Decription

Endo Pharmaceuticals Holdings Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features: 

• Detailed information on Endo Pharmaceuticals Holdings Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Endo Pharmaceuticals Holdings Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Endo Pharmaceuticals Holdings Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Endo Pharmaceuticals Holdings Inc.
• Intelligence on Endo Pharmaceuticals Holdings Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Endo Pharmaceuticals Holdings Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Endo Pharmaceuticals Holdings Inc. and the factors that influence its strategies 
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Endo Pharmaceuticals Holdings Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Endo Pharmaceuticals Holdings Inc.’s business structure, strategy and prospects

Companies Mentioned:

Endo Pharmaceuticals Holdings, Inc.

Paper Highlights:

Endo Pharmaceuticals Holdings (Endo) is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and central precocious puberty. The company primarily operates in the US. Endo is headquartered in Chadds Ford, Pennsylvania and employed 1,487 people as of February 19, 2010. The company recorded revenues of $1,460.8 million during the financial year (FY) ended December 2009, an increase of 15.9% over FY2008. The operating profit of the company was $390 million during FY2009, an increase of 0.7% over FY2008. The net profit was $266.3 million in FY2009, an increase of 4.3% over FY2008.